Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients

Fig. 5

LASSO-based radiomic feature selection process and preliminary evaluation of the radiomics model. Correlation analysis of radiomic features (A). LASSO model accuracy score plot (B). LASSO path diagram (C). LASSO model feature weight plot (D). Kaplan-Meier survival analysis between low-risk and high-risk groups (E). Radiomics scores for each patient in the training group (F)

Back to article page